Functions of TGF B-1:
Quick facts:
- TGF B-1 regulates immune and tissue cell growth and proliferation.
- TGF B-1 is involved in maintenance of tissue homeostasis.
- TGF B-1 helps regulate effects in the innate immune system.
- TGF B-1 is an immune suppressor (although it can upregulate the immune system in some instances)
The TGFβs are involved in many cellular processes, including growth inhibition, cell migration, invasion, epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodeling and immune-suppression. However, although normally dynamically regulated and involved in maintenance of tissue homeostasis, TGFβs are often chronically over-expressed in disease states, including cancer, fibrosis and inflammation, and this excessive production of TGFβ drives disease progression by modulating cell growth, migration or phenotype. The TGFβ signalling pathway has therefore become a popular target for drug development.
Disruption of the TGF-β pathway has been implicated in many human diseases, including solid and hematopoietic tumors. As a potent inhibitor of cell proliferation, TGF-β acts as a tumor suppressor; however in tumor cells, TGF-β loses anti-proliferative response and becomes an oncogenic factor.
The TGFB family of cytokines consists of the following:
The transforming growth factor (TGF-β) family of growth factors controls an immense number of cellular responses and figures prominently in development and homeostasis of most human tissues.
- TGFβs,
- activins,
- inhibins,
- Nodal,
- bone morphogenetic proteins (BMPs),
- anti-Müllerian hormone (AMH; also known as Müllerian-inhibiting factor)
- as well as growth and differentiation factors (GDFs)
Research shows that TGF B-1 has a role in activation of autoimmunity as well as suppressing autoimmunity. TGF-beta, together with IL-6 and IL-21, promotes Th17 cell development. Th17 cells have been identified as a lineage distinct from Th1 and Th2 cells, and are required for induction of several autoimmune diseases, including collagen-induced arthritis, experimental autoimmune encephalitis (EAE), and inflammatory bowel disease (IBD), and also for the ability to clear bacterial infections of the intestine and the airways.
It appears TGF beta-1 is not immune suppressive if T-reg cells (known by their CD4+/CD25+ cell surface markers) are in normal range. If T-regs are low, TGF- beta 1 can transform them into pathogenic T-cells in tissues, as happens in CIRS cases. This transformation may depend in part on IL-6. The net result is a positive feedback loop in which more TGF-beta gets produced.
TGF-β as a tumor promoter:
TGF-β acts as tumor suppressor in normal epithelium; it inhibits cell proliferation and induces apoptosis. Yet, during tumor progression, sensitivity to these effects of TGF-β is frequently lost and, in later stages, TGF-β signaling has pro-oncogenic function. Several activities have been described to TGF-β that would favor tumor progression [L].
Other references:
https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-183
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.